<SEC-DOCUMENT>0001437749-21-006476.txt : 20210318
<SEC-HEADER>0001437749-21-006476.hdr.sgml : 20210318
<ACCEPTANCE-DATETIME>20210318161426
ACCESSION NUMBER:		0001437749-21-006476
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210318
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210318
DATE AS OF CHANGE:		20210318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		21754491

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20210318_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/18/2021 11:23:44 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>dffn20210318_8k.htm</title>


</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 8-K</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>the Securities Exchange Act of 1934</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported): March 18, 2021</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>000-24477</b></p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 33.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(State or other jurisdiction of incorporation)</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Commission File</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number)</p>
			</td>
			<td style="vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(I.R.S. Employer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>1317 Carlton Avenue, Suite 200</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Charlottesville, Virginia</b></p>
			</td>
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>22902</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align: top; width: 50.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(434) 220-0718</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-width: thin thin 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 42.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Title of each class</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Trading Symbol(s)</p>
			</td>
			<td style="border-width: thin thin 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 42.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 24.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">DFFN</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</b>&#167;&#8201;<b>230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</b>&#167;&#8201;<b>240.12b-2 of this chapter).</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Emerging growth company&nbsp; &nbsp; &nbsp;&#9744;</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp; &nbsp; &nbsp; &nbsp; &#9744;</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 7.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Regulation FD Disclosure</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain information concerning the business, clinical studies, development plans, and financial position of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;) that we expect to use at certain conferences, meetings, and presentations will be made available on our website, www.diffusionpharma.com, under &#8220;Investors &#8211; Presentations&#8221; on or about March 18, 2021. Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in the presentation is summary information that is intended to be considered in the context of the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in this Current Report on Form 8-K. The information in this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as previously set forth by specific reference in such a filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 8.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On March 18, 2021, the Company issued a press release announcing the dosing of the first participants in the Company&#8217;s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (&#8220;TSC&#8221;), utilizing a transcutaneous oxygen monitoring device to evaluate the effects of TSC on peripheral tissue oxygenation. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item</b>&nbsp;<b>9.01 </b>&#8211;<b> Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(d) Exhibits </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Number</b></p>
			</td>
			<td style="vertical-align:top;width:89.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:89.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:89.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_235197.htm" style="-sec-extract:exhibit;">Press Release, issued March 18, 2021</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Dated: March 18, 2021&nbsp;</p>
			</td>
			<td colspan="3" rowspan="1" style="width: 11%;" valign="top" width="50%"><b style="font-size: 10pt;">DIFFUSION PHARMACEUTICALS INC.</b></td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 6%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 29%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 6%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 29%;" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" style="text-align: left; width: 6%;" valign="top" width="50%">&nbsp;</td>
			<td style="text-align: left; width: 5%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 29%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 6%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Name:</p>
			</td>
			<td style="width: 29%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">William Elder</p>
			</td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 6%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">Title:</p>
			</td>
			<td style="width: 29%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">General Counsel</p>
			</td>
			<td style="width: 15%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_235197.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 3/18/2021 11:20:13 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_235197.htm</title>


</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0; text-align: right; margin-top: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt;"><img alt="img.jpg" src="img.jpg"></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diffusion Pharmaceuticals Doses First Participants in TCOM Study</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHARLOTTESVILLE, Va., March 18, 2021 --&nbsp;<b>Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)</b>&nbsp;(&#8220;Diffusion&#8221; or the &#8220;Company&#8221;), an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most, today announced that it has dosed the first participants in the Company&#8217;s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (&#8220;TSC&#8221;), utilizing a transcutaneous oxygen monitoring (TCOM) device to evaluate the effects of TSC on peripheral tissue oxygenation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The TCOM trial is the first in a series of three, short-term studies Diffusion plans to conduct in the United States in 2021. Together, the oxygenation trials, which the Company plans to fund with cash-on-hand, will serve as a prospective exploration of the relationship between the level of TSC exposure (dose) and response (change in oxygenation). The results will be used to inform the next phases of clinical development and commercialization plans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The TCOM trial is a randomized, double blind, placebo controlled, pharmacokinetic, pharmacodynamic study of TSC that will enroll up to 30 healthy volunteers. Trial participants will be randomized into one of six subgroups and receive a single intravenous dose of TSC or placebo. Patients receiving TSC will be randomly assigned to receive one of five different doses ranging from 0.5-2.5 mg/kg. All trial participants will receive supplemental oxygen during equivalent monitoring periods before and after TSC is administered while being continuously monitored with transcutaneous oximetry sensors applied to the lower extremity. The primary endpoint will be the change in TCOM readings after TSC administration relative to the participants pre-dose baseline TCOM readings. Diffusion anticipates that the TCOM trial will be completed in 2Q21.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;We anticipate the TCOM trial will provide important information about TSC&#8217;s ability to enhance oxygen delivery to tissues,&#8221; said Christopher Galloway, M.D., Chief Medical Officer of Diffusion. &#8220;We are excited to obtain objective evidence of the drug&#8217;s exposure-response relationship with oxygenation and eager to incorporate that knowledge into the next phase of our clinical development strategy.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Near-term Clinical Strategy</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the TCOM trial, the Company plans two additional oxygenation trials as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Hypoxia Trial: </b>This is expected to be a double-blind, randomized, placebo-controlled study which will evaluate the effects of TSC on maximal oxygen consumption, or VO2, and partial pressure of blood oxygen, or PaO2, in normal healthy volunteers subjected to incremental levels of physical exertion while exposed to hypoxic and hypobaric conditions.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DLCO Trial: </b>This is expected to be a double-blind, randomized, placebo-controlled study which will evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs, also known as DLCO, in patients with previously diagnosed interstitial lung disease who have a baseline DLCO test result that is abnormal. DLCO will act as a surrogate measure of oxygen transfer efficiency, or uptake, from the alveoli of the lungs, through the plasma, and onto hemoglobin within red blood cells.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="img.jpg" src="img.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion plans to initiate both of these studies in 3Q21.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company anticipates that positive data from one or more of the three oxygenation trials will guide the next steps in the TSC clinical development strategy, which will focus on demonstrating the therapeutic benefits of TSC in a relevant patient population affected by hypoxia. The Company expects to identify and announce this specific, hypoxia-related indication on which it will focus further clinical development in 4Q21. The Company then plans to initiate a Phase 2 clinical outcome study evaluating TSC in the announced indication, during the first quarter of 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. Diffusion&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion&#8217;s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development. For more information, please visit us at www.diffusionpharma.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company&#8217;s anticipated cash runway, its near-term strategic priorities, and anticipated timelines for the initiation, completion, and announcement of data from the Company&#8217;s [ongoing and] planned oxygenation trials. The Company may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control, and as a result the Company&#8217;s actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risk and uncertainties include, among other things, those related to: the Company&#8217;s ability to design, initiate, enroll, execute, and complete its ongoing and planned studies evaluating TSC; general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s filings most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified) and, except as required by applicable law, rule, or regulation, the Company undertakes no obligation to update any such statements after the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors:</b>&nbsp;&nbsp;<br>
Tiberend Strategic Advisors, Inc.&nbsp;<br>
Maureen McEnroe, CFA/Miriam Weber Miller&nbsp;<br>
(212)&nbsp;375-2664 / (212) 375-2694&nbsp;&nbsp;<br>
mmcenroe@tiberend.com&nbsp;/&nbsp;mmiller@tiberend.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b>&nbsp;&nbsp;<br>
Jeffrey Freedman&nbsp;<br>
RooneyPartners&nbsp;&nbsp;<br>
(646) 432-0191&nbsp;<br>
jfreedman@rooneyco.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img.jpg
<TEXT>
begin 644 img.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" != -T# 2(  A$! Q$!_\0
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MU1?UKZ-T+7K'Q1H]OJ&FWEKJ-A=H)8+FUF66&=#T974D,/<&OR$_:!_X-'/
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MI!\ M<^(6A:/K/A/2?#NIRZ7?#6VA0(\<$4[R!T<KY825<LVW&&R,<U_-O\
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MACGD8KD_^#OG_DAWP8_[#FH_^B(:^A/^#93_ )1/>&/^PWJO_I0: Z'X8_\
M!,3]EGPK^UE_P4@\$_"[Q8-2/A;7[^_MKH65P(;G;#:7,J;7*D#YXDSQR,],
MU^BO_!8?_@@[\"/V(/V ?&'Q(\$KXR_X231;C3XK4W^K+/;@37L,+[D$0S\C
MMCD<X/:OC'_@A9_RFK^%_P#V%M6_]-U[7[._\')'_*(7XC?]?FD?^G*VH![G
MY@_\&[W_  2Z^%__  4+M/B/J_Q!'B+[9X%O]*;3/[,U 6J_O1<N^\;&+<PI
MC!'>L[_@ZF_Y2=6?_8FZ=_Z.NJ^G?^#/C_D3/CU_U^Z'_P"@7]>$?\'97PMU
M/PY^W=X/\6202?V-XE\(PVMM<;?D:XM;B<31Y]56:!C_ -=!0'4_7@_\H9O^
MZ+_^X.OQD_X-5<_\/.+_  ./^$+U'/M^_M*^AM/_ .#BKX:7?_!)VV^&D.A^
M)[WXN3^"1X'33([(&TDG-I]B%T)@W*%<2; N\L=F,?/7SO\ \&K9,/\ P4\O
M5<%6_P"$-U%<'@@^=:_X4!T.-_X.![_7T_X+"^*Y/B-;:M<^';=]-_LRWCD\
MOSM&$,9VVSL"HW-]HR<$"4R9Y!K]%/\ @F3\"O\ @GO^T1\</!7C'X'K>>'O
MB-X,?^T8/#^HZI=1WLKK$REI(+EY$FV;MY:W<X902<#%=_\ \% OVX_V&_CK
M\8O$_P %OVA8XDUKP-.MLFI7NEW.(9)(8Y6^RWEH&ECV[PKJVP%T.0P K\2?
M$.B>&O '_!3S2K/]ESQ!XA\2:/:^*=/'@W49XGBO)YV>([ "B,R+,70%D7<@
M!(Y- 'W[_P '?_\ R5+X(?\ 8*U7_P!'6U?7'["WQRO/V=_^#>;P!XDTQS'J
MR:)-9V,@QF*:;49XQ(,\90,SC/=!7R1_P> #_BZ/P0_[!6J_^C;:OK#]BKX)
MW_Q__P"#=_P#H&DQ-/JXT66^LH4&6GDAU&>0QJ.[,H91[L*YL9S^PG[/XK.W
MW'O<++"/.<(L?;V/M(<]]N7F5[^5M_(\O_X):_L::)^V-X\\4Z[XZ:]U+2M#
M$1> 7#QM?7$[2'+R [\ 1N3@@DLO/4'+_P""F?[)^F?L5?&W0+[P3/>Z?I6L
MP?;+*,W#-+87$+@,$DSOP,QL"3N!8\\ UM_\$H?VR/#W[)OC7Q3H/CB6XTK2
M]?6$K=^0\HM+B$N-KHH+882-R <%5XP21E?\%0_VK-(_;(^-WA_3?!"W6JZ7
MH<!L[6=;=U>_N9G&[RXR-^WB-1D D@\<C/P[^J?V8FK>UO\ /?\ *W]7/Z_I
MOB7_ (B!.,^?^S_9^?LK<B_[=YO:;_:M?[)^EW[&?QHG^/G[+OA#Q;?LIOK^
MR*7LF H>:%VAD?'0;FC+8[;J]+L[^#48?,MYHIX\XW1N&&?3(KYI\&?\$_+/
MQ3^QM\/?AUXGU76]*70A]MU2WTRZ$8NI)3)+);R'!5E623&[!^X<8SFO!_AA
M\-(/V3O^"JNA>!_AGJ^K7GA_4K#S=?T^:<3);$Q2LR2$ #Y56*121D%P,\X/
MU7URO1C256&CY4W?6[\K?J?S>^%LHS7$9A/+<3RRI>VJ1A[/W/9PD[?O.;2\
M;<ONVV3=V?D)_P %WFN[7_@L[\5VTZ>6TOEU33&MIXI#&\,O]G695E8<J0W.
M1TK[!_X**_\ !N'\//V0_P#@FWK7C_0O$_B;4/B%X'L[>^U2:ZEB.GZJ&ECC
MG1(@@:(+YA9#O8X3#9+;A\B?\%T_^4U?Q0_["VD_^FZRK]W?^"X7_**#XV?]
M@)?_ $IAKUS\R/SY_P"#0GXPZO</\8_ 4UQ++H=LEAKMI S?);3L989F4?[:
MK#G_ *Y"OVRK\(/^#0?_ )+I\9?^P#8?^E$E?N_0)[A1110(**** "OAOX@_
M\&Z7[*GQ(\6ZEK=YX)UFWO\ 5[F2\NFMO$5ZJO+(Q=V"M(P&23P.!V%?<E?.
M_P"T-_P5D_9U_91^*ESX)^(7Q5\/>&?%-C%%/=Z?<)/(]G'*H>-Y6CC98U92
M""Y P: /-OAA_P &^/[)GPMU9+Z'X6P:U<QD%3K6J7=_%QZPO+Y3?\"0U]@^
M%/"6E>!/#MII&AZ9I^C:381B*ULK&V2WM[9!_"D: *H]@*\R\9?MU?"_P;HG
MPMU3_A)[76-'^,VO6_ASPCJ.CC^T;/5+N>*66+$L6Y1&5AD^<G:"N":]=H \
M:_;$_8"^%/[>^A:+IOQ4\,MXDL_#T\ES8(NH7-GY$DBA7.8)$+9"C@YZ5T7[
M,'[+'@;]C;X26O@;X=Z,=!\,6<\MS#:&[FNBLDK;G.^5V<Y/J>.U>AT4 ?*_
MP&_X(L_LW_LS?&[2_B+X+\ R:3XOT6:6>SO3KE_.(7EC>)SY<DS(<I(XY4XS
MQT%>U_M+_LS>"_VOO@[J7@+X@:2VN>%=7>&2ZLUNIK8R-%*LL9\R)E<8=%/#
M<XYXKO:* /%/V-_^">7PC_8#LM?M_A3X7?PU%XG>"34@VI75Y]H: 2"+F>1]
MN/-?[N,[N>@K>_:L_8[^''[;7PR;PC\3/#%GXFT82_:(!(SQ3V4V"!+#*A5X
MWP2,J1D$@Y!Q7IM% 'R)^RC_ ,$-/V</V.OB7;^,?"W@N:^\2V#^987NM7\E
M^=.?L\2,?+5QV<J67L174_LO_P#!(_X!?L:_%Z3QW\.O!,F@>)Y;::T:[_MB
M]N08I2"Z^7+,R<E1_#QCBOI*B@#X\_:=_P""$/[-7[6/Q&U+Q?XC\%WEEXFU
MJX>ZU"_TG5;BU:]E8Y9WCW&/<2220@)/6NI_8Z_X(_\ [/\ ^PMXG&O^ O T
M,?B959(]9U.ZDO[V!6&&\II"5BR"03&JD@D$D&OIJN9\;?&?PG\./ASK_B[7
M/$6D:=X9\+0SW&KZE+<K]GTY(03+YC G:4QR.O;&: /+?VQO^":/P8_;ZU70
M[WXJ^$W\27/AN*6#3W75+NS\A)2K.,02H&R47[V<8XKTCX"? CPM^S)\(=$\
M">"M-.D>%_#L306%F;B2?R$:1I"-\C,[?,['DGK6[X,\8Z5\1/!^E>(-"O[7
M5M$UVSAU#3[ZVD$D%Y;S()(I48<,K(RL".H(K3H \1^./_!._P"$W[07B&76
M-=\,I%K%PQ::]L)FM9)V/5G"G8[?[3*6]ZN? ;]@GX6?LX:L-2\->&81JR_=
MO[R5KJ>/C'R%R0AQW0 \FN@_:K_:@\(?L8?L_P#B/XF^/;RZT_PCX4BCGU&X
MMK5[J6)9)HX5(C0%F^>1!P. 2>@KO[>=;F!)$Y610R\=CS7-]3PZG[7D7-WL
MCZ"7%>=2P?\ 9[Q=3V-K<G/+EMVM?;RV/ O^"@_[3'BW]GGX:V</@?PSJ>N^
M(_$/G16]S;VC7$.EJ@3=(ZJ#ESY@V \'#$YV[3\V_P#!.OXI1_"KQQ:P:E\,
M/B'?>.?'-ZD&M>*-3A8K$9906QE,K$"0S$MEB,D\*!]]^/O'>C_"WP)K7B;Q
M#J%OI.@>'+"?5-3OK@XBLK6"-I997/95168^P-+X!\=Z1\4? NB^)O#VH6^K
M:!XBL(-4TR^MSF*]MIXUEBE0]U9&5A[$5S5L#4J8A5_:;;*R=N_S?<][*N,<
M'@\DJ9/+!*3J7YYJI*+EORW26L8Z>[?E;5VKGS;\>?\ @BQ^S?\ M,_&[5/B
M+XT\ RZMXOUJ:&>\O1KE_ )GBC2)#Y<<RH,)&@X49QSU->]_'7X'^&?VD_A)
MKG@;QEIYU7PQXC@%MJ%H)Y(#/&&5L;XV5UY4'*D=*ZVBO2/@3P/]CO\ X)D?
M!7]@C7M9U+X5^$7\-WOB"WCM;^1M4N[SSHT8LHQ/*X7!)Y&*]\HHH **** "
MBBB@ K\N+']J:]_9H_X+>?M=I8_"'XK_ !;F\1>&_!$*VW@S2;>]BLW2QO-J
MWDD\\20K)YAVL<@B.3.,#/ZCUX5\&OV,#\)?V[/C5\:?^$B^WCXO:;X?T\:1
M]B\O^RO[+AGBW>=O/F^;Y^<;%V[>K9X /S%^*/[*7Q4_9/\ V8/V2-#ET_PM
MX/\ B'XO_:AF\4Z7X=FE-]HW@8:E%JDT-CF H)H[96W,D3*K/N56P=]?97[,
M7QS^-/P$_P""F&M?L^?%WXDZ7\6-%U[X=/\ $30/$Q\.VV@W>D&"_2SN;*:*
MW/E21?O%D20_, "K$]:]Q_;,_8R/[6OC/X)ZL/$/]@_\*?\ B!:>.3%]B^T_
MVKY%O<0_9L[U\K=Y^=^&QMQM.<CF_CO_ ,$X[']H#]LF_P#B?JOB:YMM)U?X
M2:K\*;W1K:VV3M#?W23O=QW._P"1E52H7RSR0V[C! /C#PI_P5(\8_#K]K?X
M,VVC_M"7_P"T3X*^)GCN+P)KB)\*3H7ANRDN5G$5QI>M1Q"&9HIH@#";BY,B
M%R&&PD>X?L8_&S]H?]J;]O#XX6=]\0O#^B_"+X(?$>\T2+2X/#L$VI>)87L8
M9([&2X)'V>&W+K*)45I96E*LP5 #F>#O^"-OQ2_X1C]G_P ,>+?V@--UKP9^
MS7XHT76O"NDZ=X%CTXZC;Z:K0Q+?R_:G,EQ]G8QK)&(T4L[LDK,-OTO^R)^Q
MF?V6?B+\<->/B'^V_P#A<?C>7QB(/L7V?^R=]K;V_P!GW;V\W'D;M^%^]C;Q
MD@'YKZ#_ ,% /VP=-_X)#^'/VS[WXJ>"]3LM!FB%_P##\^$+>&V\46*ZP=,D
MEGO5/FV]T['>H@"Q(BJ"K,6-?4OA/XQ_M#?LG?\ !1WX)_#_ .*OQ.\._%/P
MM^T-I^NHMI9>%H=&_P"$-U33;1+XK:R1LTD]H\9>,?:"T@*ABW.*U/\ AS:_
M_#E7_AD+_A87S^1Y'_"5?V+_ -1G^T\_9?._[9_ZW_:_V:]M^/W[&+?'#]L3
M]G_XKCQ%_9H^!T^O3'3/L/F_VS_:>G?8L>;O'E>7]_[K[NGR]: /@G]LK_@J
MAXN_9:^*VJ>+/"'[15W\7=,\,^.K31M?\$Z?\*C_ ,(QIME<:A':R63:_#&R
MPW\"3+\\ETP>5-IA4N$'T1XN^,OQN_;B_;A^*_PM^$_Q(LO@EX*^!0TRQUK7
MX_#EKKNL>)-5OK47?DPI=9@@MH86C#,8V=W8@';ROFNJ_P#!!_XAS_LBW7[/
M5A^T-!I_P6TS7!KGA_3AX)CDU;(U4:FMOJ%X;K%S$DVX@QQPR,VQF?:AC;W+
MXR_\$Z_'^B_M<>)OC1\!/BW9?##Q%\0[*SL_&FC:YX8'B#1/$$EI&8K6\$8G
M@E@N8XCY>Y)"KJ!E<Y) /!_VR_\ @HCXN^"7[3_A;]GO5?CE=^ )_#/@>V\1
M^+_B+IOPW?7M5\0WT\TD$%K;6$,%Q;6:$0RS2R2(XYCCCP=S#E_#/_!6?XOZ
MY^RKX#OQJR3ZY;?M(:'\++OQ3+X2ETB+QUX>NYD(ODLKN,-:R2PRA'"#Y)(G
M*$!ACZ?^)_\ P3R^)M]\5?"7Q<\#?&FQ\,_&_3?"T7A+Q5JMYX16\\/^.+2.
M4SIY^FK<HUO)',\CQR13[E61D)935W]HC_@GOXX_;!_8P3P'\1_BS:R_$K2O
M$5IXL\/^-/#_ (733H= U&SG6>S:.Q>>82)&0RMOERX<\J<8 (OVF/VA?B!I
M?_!3;X3_  =\->)(O#WA[X@> /%.I74PTV"[EMK^U^RI:7*^8#GRC,S>7G8^
M,,"*^'OV"-+^)O[/_P#P23_:Y^(4_P 4(O%FF>'I?B0;3PYJ7A#319MJUM=7
M#MJ4K;6,HE:)RULX,($I7!"BOLOX._\ !-OXFVW[;?@/X\_%7XX0^/\ Q3X/
MT'5/#K:5I_A6/1](6VN_(*&WC$\CI('CD:621I#+NC4")8@#C>$_^"2_C'P=
M\&OVD/A/;_%O3Y_A/\<(/$DVCZ=/X7SJ?A2^UHLTSM=+< 7,$;22E8S&C'>,
MR#;R <E'^UO\8?VAO%W[/_P$^%7B7P]\./$_B3X.Z?\ %#QIXRD\/PWYTRQ<
M06L5MIU@Q6W$LMRTF=X,<4:<(>!7>?M2>*/&G[(/[+_AO3O'_P"UU+X>\2ZA
MK\D$7B>'X;V5_KWB.-D8Q:?9Z9 DD;SJ<,TD=M(2H.43.X6OB7_P2OU^$_!G
MQ?\ "WXI-\//C#\'?!T'@4>()M!34],\4:0D<0DM+VQ:5"8S+$)4*3!HV8G+
M'!%/XJ_\$X_C1\4O%'PA^)ES\<O"P^.7PBNM9%EJY\!9\/WEAJD4<,UH^G_;
M?-5D6)-LRW(8_,&!!X /B+]JW]M[QC^UE_P0G_;6\-^.-2OO$>L?"?6;'1+;
MQ!?^%I?"]_K=C-<Z=<P2W6FR*AM[@"1U8!$5@$8*,Y/TW^WY^V3\1/A/^VGX
M=\#:M\8_^&9/A5J7A>TG\/>-)_!EOK>G>)M<DF=);*[O+D-!9I%&L1$9\II/
M,)\Y?E%:7BK_ ((A:_X^_9@_:?\  7B/XU7&OZW^TOJ>FZO>^(;CPU'$VE7%
MLEJ)%6WCG"O$3;[8T#*8XRBEI"I=O5?VZOV'_C%^V!X?\3^ ].^,GA/PU\(?
M'.BIH>LZ-=^ EU/5;:(H4N'M+PW:(LDJGY6D@<PL R<@4 =S_P %*2Q_X)B_
M'W=.MTW_  J_Q%NF4 "8_P!DW'S #@ ]>/6OC2T_:)^,O@7X1_\ !-_X5?"+
MQ1X>\*M\:/AT]AJU[J^C+J4=FEEX;L+I+J--RLTL2^<4CWJCNZ"3*@BON_XJ
M_LMV/CC]B/Q)\%-)U&XTG3=7\#W7@BSO[A?M<ME#+8-91S."5\UD5@Q&5W$'
MD9S7DNB?\$RFT?QM^Q[K'_"9^9_PREH%[H;1?V7C_A)OM&BPZ7YN?-_T?;Y7
MF[<29W;<C&Z@#PO1/^"C'Q/_ &!-:_:G\)?&SQ-9_&5_@7X*L/'_ (>\06^C
MP:%>:Q!>">,6%U#;@PHRW,*(LJ+RCEF'11[I^QE\(/VFM4U3PE\0_BS\>-+O
M[76K'^T-7^'FB^"K*WTBP,\!:.W@OB6O"87="9'=O,\LC:H;(N_$;_@F'X>^
M,_[2?QK\8>+M6;5O"_QL^']EX U+0$M?)DM88&N2TZ7.\_.WVCY<("C(#D]L
MS]ES]C?]HO\ 9]BTGPMJO[26E>+_ (=>&]-GTW3$N_ ,2>(I(_LSPV?VB^%T
M8I#;L8G+_9PTWE8?&YC0!]:45Y[^RK\-/&7P>_9\\,>&OB#X\F^)WC+2;9HM
M4\3RZ='ISZM(9'97,$9*IM1E3@DG9D\DUZ%0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
